(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/161887 A1

(51) International Patent Classification:
A61K 31/505 (2006.01) *A61P 17/00* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/IB2023/051787

(22) International Filing Date:
27 February 2023 (27.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/314,572 28 February 2022 (28.02.2022) US
63/369,016 21 July 2022 (21.07.2022) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **BHATTACHARYA, Souvik**; 420 Thicket St, Weymouth, Massachusetts 02190 (US). **BIETH, Bruno**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **CENNI, Bruno**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GRAHAM, Gordon**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **JUHNKE, Michael**; F. Hoffmann-La Roche AG, Building 10/Room O02, 4070 Basel (CH). **LOESCHE, Christian**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **RAPP, Karin**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SIN, Kim-Hien**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **ZIERER, Jonas Benjamin**; Novartis Pharma AG, Postfach, 4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2023/161887 A1

(54) Title: REMIBRUTINIB FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA

(57) Abstract: The present disclosure relates to methods for treating and/or preventing Hidradenitis Suppurativa in a subject having such disease or condition comprising administering a therapeutically effective dose of LOU064. Also disclosed are medicaments, dosing regimens, pharmaceutical compositions, combinations, dosage forms, and kits for use in the disclosed uses and methods.